Dr. Rahul S. Shinde, assistant professor in Wistar’s Ellen and Ronald Caplan Cancer Center, researches potential new therapies for treatment-resistant cancers like pancreatic cancer. In this interview, he shares insights about the future of pancreatic cancer therapy. Dr. Rahul S. Shinde: Actually, although we now have a 13% five-year survival rate that may seem low, it nevertheless represents a vast improvement over what the outlook used to be. Just a few decades ago, that 13% was closer to…